Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

NewAmsterdam Pharma (NAMS) EBIT Margin (2023 - 2025)

NewAmsterdam Pharma's EBIT Margin history spans 3 years, with the latest figure at 334743.75% for Q4 2025.

  • For Q4 2025, EBIT Margin rose 33508222.0% year-over-year to 334743.75%; the TTM value through Dec 2025 reached 233.68%, up 15323.0%, while the annual FY2025 figure was 233.68%, 15323.0% up from the prior year.
  • EBIT Margin for Q4 2025 was 334743.75% at NewAmsterdam Pharma, up from 15845.69% in the prior quarter.
  • Across five years, EBIT Margin topped out at 334743.75% in Q4 2025 and bottomed at 15845.69% in Q3 2025.
  • The 3-year median for EBIT Margin is 1996.0% (2024), against an average of 24893.71%.
  • The largest YoY upside for EBIT Margin was 33508222bps in 2025 against a maximum downside of -1575980bps in 2025.
  • A 3-year view of EBIT Margin shows it stood at 6360.4% in 2023, then surged by 95bps to 338.47% in 2024, then skyrocketed by 99000bps to 334743.75% in 2025.
  • Per Business Quant, the three most recent readings for NAMS's EBIT Margin are 334743.75% (Q4 2025), 15845.69% (Q3 2025), and 186.13% (Q2 2025).